



DATE: August 14, 2008

Recall of Boston Scientific NexStent® Carotid Stent and Monorail® Delivery System

On June 6, 2008, Boston Scientific initiated a voluntary recall of all unexpired units of the NexStent® Carotid Stent and Monorail® Delivery System. The products affected by this recall were distributed to hospitals worldwide with the exception of Japan. It is important to note that this recall does not affect stents that have already been implanted, nor any other Boston Scientific products.

Boston Scientific has initiated this recall due to reported complaints involving a detachment of the tip from the stent delivery system. Potential health hazard events resulting from this type of failure include increased procedure time, vessel wall injury, stroke and/or emergency surgery to remove the detached tip. Since the potential for the tip to detach occurs during delivery of the stent, patients who have already received a NexStent Carotid Stent are at no additional risk with respect to this product issue.

Boston Scientific has notified all affected hospitals through detailed recall notification letters, including instructions on how to return recalled product. The total number of manufactured devices affected by the recall is 2,690. Of that total number, 2217 units were distributed from June 19, 2007 through May 5, 2008, and the additional 473 have remained in the control of the Company. At this time, all affected U.S. hospitals have responded to Boston Scientific, and a significant number of the distributed devices have been returned to the Company.

The Company is working with the U.S. Food and Drug Administration and has notified officials in other countries of this recall. Boston Scientific has requested that this product no longer be used on patients and that it be returned to the Company. Customers with additional questions may contact Boston Scientific at 1-800-811-3211.

The NexStent® Carotid Stent and Monorail® Delivery System is used in conjunction with the FilterWire EZ™ Embolic Protection System and is indicated for treatment of patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet specific criteria.